NextCure Statistics
Share Statistics
NextCure has 28.01M shares outstanding. The number of shares has increased by 0.26% in one year.
| Shares Outstanding | 28.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.31M |
| Failed to Deliver (FTD) Shares | 2.27K |
| FTD / Avg. Volume | 2.65% |
Short Selling Information
The latest short interest is 73.77K, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 73.77K |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.35% |
| Short Ratio (days to cover) | 1.89 |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is -1.08.
| PE Ratio | -0.51 |
| Forward PE | -1.08 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.28 |
| P/FCF Ratio | -0.59 |
| PEG Ratio | n/a |
Enterprise Valuation
NextCure Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 16.38, with a Debt / Equity ratio of 0.05.
| Current Ratio | 16.38 |
| Quick Ratio | 16.38 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.94 |
| Cash Flow / Debt | -8.9 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.55% and return on capital (ROIC) is -55.89%.
| Return on Equity (ROE) | -0.55% |
| Return on Assets (ROA) | -0.49% |
| Return on Capital (ROIC) | -55.89% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -764.91K |
| Employee Count | 82 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -2.7% in the last 52 weeks. The beta is 0.79, so NextCure 's price volatility has been higher than the market average.
| Beta | 0.79 |
| 52-Week Price Change | -2.7% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 35.05 |
| Average Volume (20 Days) | 85.89K |
Income Statement
In the last 12 months, NextCure had revenue of $0 and earned -$62.72M in profits. Earnings per share was $-2.25.
| Revenue | 0 |
| Gross Profit | -3.68M |
| Operating Income | -67.64M |
| Net Income | -62.72M |
| EBITDA | -59.04M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.25 |
Balance Sheet
The company has $13.08M in cash and $6.61M in debt, giving a net cash position of $6.48M.
| Cash & Cash Equivalents | 13.08M |
| Total Debt | 6.61M |
| Net Cash | 6.48M |
| Retained Earnings | -324.48M |
| Total Assets | 90.34M |
| Working Capital | 70.02M |
Cash Flow
In the last 12 months, operating cash flow was -$52.97M and capital expenditures -$820.00K, giving a free cash flow of -$53.79M.
| Operating Cash Flow | -52.97M |
| Capital Expenditures | -820.00K |
| Free Cash Flow | -53.79M |
| FCF Per Share | -1.93 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NXTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -208.33% |
| FCF Yield | -177.85% |
Analyst Forecast
The average price target for NXTC is $4, which is 270.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 270.4% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -5.69 |
| Piotroski F-Score | 3 |